Upgrade to SI Premium - Free Trial

Outlook Therapeutics (OTLK)

0.75 -0.04 (5.06%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/17/25 *Est.)

Latest Headlines

Form 4 Outlook Therapeutics, For: Jun 02 Filed by: Haddadin Yezan Munther June 3, 2026 6:03 PM - SEC Filing Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments June 1, 2026 9:31 PM - SEC Filing Form 4 Outlook Therapeutics, For: May 28 Filed by: Sukhtian Ghiath M. June 1, 2026 9:30 PM - SEC Filing Form DEFA14A Outlook Therapeutics, June 1, 2026 5:02 PM - SEC Filing Form DEF 14A Outlook Therapeutics, For: Jul 16 June 1, 2026 5:00 PM - SEC Filing Form 8-K Outlook Therapeutics, For: Jun 01 June 1, 2026 9:15 AM - SEC Filing Outlook Therapeutics resubmits drug application to FDA after appeal win June 1, 2026 8:47 AM - StreetInsider Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) June 1, 2026 8:46 AM - StreetInsider Form 8-K Outlook Therapeutics, For: May 29 May 29, 2026 4:32 PM - SEC Filing Form 424B5 Outlook Therapeutics, May 29, 2026 8:30 AM - SEC Filing Form 8-K Outlook Therapeutics, For: May 28 May 28, 2026 5:51 PM - SEC Filing Outlook Therapeutics prices $5 million stock offering at $0.59 per share May 28, 2026 4:00 PM - StreetInsider Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 28, 2026 4:00 PM - StreetInsider Form 4 Outlook Therapeutics, For: May 27 Filed by: Sukhtian Faisal Ghiath May 27, 2026 3:29 PM - SEC Filing Form 4 Outlook Therapeutics, For: May 26 Filed by: Haddadin Yezan Munther May 27, 2026 3:24 PM - SEC Filing Form 4 Outlook Therapeutics, For: May 26 Filed by: THURMAN RANDY H May 27, 2026 3:21 PM - SEC Filing Form 4 Outlook Therapeutics, For: May 26 Filed by: HILZINGER KURT J May 27, 2026 3:15 PM - SEC Filing Form 8-K Outlook Therapeutics, For: May 26 May 26, 2026 7:16 AM - SEC Filing Outlook Therapeutics wins FDA appeal for eye drug application May 26, 2026 7:03 AM - StreetInsider Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) May 26, 2026 7:00 AM - StreetInsider Form PRE 14A Outlook Therapeutics, For: Jul 16 May 22, 2026 5:03 PM - SEC Filing BTIG Downgrades Outlook Therapeutics Inc. (OTLK) to Neutral May 18, 2026 6:08 AM - StreetInsider Form 8-K Outlook Therapeutics, For: May 15 May 18, 2026 6:03 AM - SEC Filing Form 10-Q Outlook Therapeutics, For: Mar 31 May 15, 2026 4:36 PM - SEC Filing Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update May 15, 2026 4:05 PM - StreetInsider Form 424B5 Outlook Therapeutics, May 13, 2026 5:13 PM - SEC Filing Outlook Therapeutics enters $100 million at-the-market offering agreement May 13, 2026 4:43 PM - StreetInsider Form 8-K Outlook Therapeutics, For: May 12 May 13, 2026 4:36 PM - SEC Filing Form D Outlook Therapeutics, May 7, 2026 4:30 PM - SEC Filing Form SCHEDULE 13G Outlook Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC April 24, 2026 5:17 PM - SEC Filing Form 8-K Outlook Therapeutics, For: Apr 22 April 23, 2026 7:02 PM - SEC Filing Outlook Therapeutics completes $5 million stock offering April 23, 2026 4:05 PM - StreetInsider Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering April 23, 2026 4:05 PM - StreetInsider Form 424B5 Outlook Therapeutics, April 23, 2026 7:30 AM - SEC Filing Outlook Therapeutics raises $5 million in registered direct offering April 22, 2026 8:30 AM - StreetInsider Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 22, 2026 8:30 AM - Globe NewsWire Form 8-K Outlook Therapeutics, For: Apr 21 April 21, 2026 4:16 PM - SEC Filing Outlook Therapeutics completes FDA dispute meeting for eye drug April 21, 2026 9:05 AM - StreetInsider Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) April 21, 2026 9:05 AM - StreetInsider Form 8-K Outlook Therapeutics, For: Apr 07 April 7, 2026 4:17 PM - SEC Filing Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA April 7, 2026 12:54 PM - Globe NewsWire Outlook Therapeutics submits drug approval dispute to FDA April 7, 2026 8:56 AM - StreetInsider Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA April 7, 2026 8:56 AM - StreetInsider Form 8-K Outlook Therapeutics, For: Mar 23 March 25, 2026 5:05 PM - SEC Filing Outlook Therapeutics closes $5 million public offering March 25, 2026 4:05 PM - StreetInsider Outlook Therapeutics Announces Closing of $5.0 Million Public Offering March 25, 2026 4:05 PM - StreetInsider Form 424B5 Outlook Therapeutics, March 25, 2026 6:01 AM - SEC Filing Outlook Therapeutics prices $5 million public offering at $0.25 per share March 24, 2026 7:00 AM - StreetInsider Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering March 24, 2026 7:00 AM - StreetInsider Outlook Therapeutics announces proposed public stock offering March 23, 2026 5:30 PM - StreetInsider Outlook Therapeutics Announces Proposed Public Offering March 23, 2026 5:30 PM - StreetInsider Form 424B5 Outlook Therapeutics, March 23, 2026 5:19 PM - SEC Filing Form 8-K Outlook Therapeutics, For: Mar 13 March 16, 2026 9:00 AM - SEC Filing Outlook Therapeutics secures $18.4 million financing, extends convertible note March 16, 2026 8:06 AM - StreetInsider Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note March 16, 2026 8:05 AM - StreetInsider Form 8-K Outlook Therapeutics, For: Mar 06 March 11, 2026 5:16 PM - SEC Filing Form 8-K Outlook Therapeutics, For: Mar 10 March 10, 2026 4:32 PM - SEC Filing Full Article List